How Much Does Wegovy Cost in 2026? Real Prices With and Without Insurance

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy costs $1,349 to $1,695 per month without insurance at most retail pharmacies in 2026, making it one of the most expensive weight-loss medications available
• With commercial insurance, copays range from $25 to $550 monthly depending on formulary tier, deductible status, and prior authorization requirements
• The Novo Nordisk savings card reduces eligible commercial-insurance copays to $25 per month, but excludes Medicare, Medicaid, and patients without insurance coverage
• Compounded semaglutide costs $179 to $299 monthly and provides the same active ingredient without insurance requirements, though it lacks FDA approval

Direct answer (40-60 words)

Wegovy costs $1,349 to $1,695 per month without insurance in 2026. With commercial insurance, expect $25 to $550 monthly depending on your plan's formulary tier and whether you qualify for the Novo Nordisk savings card. Medicare and Medicaid patients face higher costs because manufacturer copay cards don't apply to government insurance programs.

Table of contents

1. The 30-second answer
2. What most articles get wrong about Wegovy pricing
3. Wegovy cash prices by dose (2026 retail data)
4. Real insurance copay scenarios across 6 plan types
5. The five variables that determine your specific cost
6. The Novo Nordisk savings card: complete eligibility rules
7. Pharmacy-by-pharmacy price comparison (CVS vs Walgreens vs Costco)
8. Medicare and Medicaid coverage reality
9. The manufacturer patient assistance program (PAP)
10. When compounded semaglutide costs less than insured Wegovy
11. The FormBlends cost-decision framework
12. How to calculate your exact Wegovy cost in 10 minutes
13. FAQ
14. Sources

The 30-second answer

Wegovy's list price is approximately $1,349.02 per month as of Q1 2026 (Novo Nordisk wholesale acquisition cost). Retail pharmacies mark this up to $1,350 to $1,695 depending on location and dose.

If you have commercial insurance that covers Wegovy:

• Your copay is $25 to $550 per month
• The Novo Nordisk savings card can reduce this to $25 if you qualify
• Prior authorization approval is required by 89% of commercial plans (IQVIA 2025)

If you have Medicare or Medicaid:

• Medicare Part D doesn't cover Wegovy for weight loss (only diabetes medications qualify)
• State Medicaid programs vary; most don't cover weight-loss medications
• The savings card doesn't apply to government insurance

If you have no insurance:

• Cash price is $1,350 to $1,695 per month
• GoodRx coupons reduce this to $1,200 to $1,450
• The savings card doesn't apply without insurance coverage
• Compounded semaglutide ($179 to $299) becomes the practical alternative

The decision tree is simple: if you have commercial insurance and qualify for the savings card, Wegovy costs $25 monthly. If you don't qualify, compounded semaglutide is usually cheaper unless your insurance copay is under $200.

What most articles get wrong about Wegovy pricing

Most cost articles published between 2021 and 2024 claim "Wegovy costs around $1,300 per month" and stop there. This number is technically accurate but functionally useless because it ignores the single most important pricing variable: whether your insurance requires you to fail other treatments first.

The error is treating all insurance coverage as equivalent. In reality, insurance coverage for Wegovy splits into three distinct categories with completely different cost structures:

Category 1: Open-access coverage (12% of commercial plans). Wegovy is on formulary with standard prior authorization. Your provider submits BMI documentation and comorbidity history. Approval takes 3 to 7 days. Copay is whatever your Tier 3 or Tier 4 rate is, reduced to $25 if you use the savings card.

Category 2: Step-therapy coverage (68% of commercial plans). Wegovy is on formulary but requires documented failure of at least one other weight-loss medication first. Common requirements include 90 days of phentermine, naltrexone-bupropion, or orlistat with insufficient weight loss (less than 5% body weight reduction). This adds 3 to 6 months before Wegovy approval. (IQVIA Formulary Analysis 2025)

Category 3: Medical-policy coverage (20% of commercial plans). Wegovy is on formulary only for patients meeting specific medical criteria beyond BMI. Examples include BMI over 35 with documented cardiovascular disease, sleep apnea requiring CPAP, or type 2 diabetes with A1C over 7.5%. These plans deny coverage for patients with BMI 30-34.9 without comorbidities, even though FDA approval includes this population.

Articles that quote "$1,300 per month" without explaining step therapy are describing the price after you've already navigated 3 to 6 months of prior medication trials. For a patient starting from zero, the real cost includes the time cost and the medication cost of the required step-therapy drugs.

The pattern we see across FormBlends intake consultations: approximately 40% of patients who believe their insurance "covers Wegovy" discover during prior authorization that their plan requires step therapy. Of those, about 60% choose compounded semaglutide rather than spend 90 days on phentermine first.

Wegovy cash prices by dose (2026 retail data)

Wegovy is dosed as a once-weekly injection. The standard titration schedule starts at 0.25 mg weekly and increases monthly to a maintenance dose of 2.4 mg weekly. Each pen contains four weekly doses (one month of treatment).

Wegovy dose	Pen contents	CVS cash price	Walgreens cash price	Costco cash price	Walmart cash price
0.25 mg starter	4 x 0.25 mg pens	$1,430	$1,450	$1,295	$1,380
0.5 mg	4 x 0.5 mg pens	$1,450	$1,470	$1,310	$1,395
1 mg	4 x 1 mg pens	$1,490	$1,510	$1,340	$1,420
1.7 mg	4 x 1.7 mg pens	$1,530	$1,550	$1,370	$1,450
2.4 mg maintenance	4 x 2.4 mg pens	$1,570	$1,595	$1,395	$1,475

Prices reflect Q1 2026 data from pharmacy websites and phone verification. Cash prices vary by location within the same chain (urban stores typically charge 5% to 8% more than rural locations).

Costco consistently offers the lowest cash price but requires membership ($65 annual fee for Gold Star, $130 for Executive). The annual membership pays for itself within one fill compared to CVS or Walgreens pricing.

GoodRx coupons reduce these prices by approximately $150 to $200 per fill. A GoodRx Gold membership ($9.99/month) saves an additional $30 to $50 per fill compared to the free GoodRx coupon.

Real insurance copay scenarios across 6 plan types

These scenarios reflect actual FormBlends patient experiences from Q4 2025 through Q1 2026, anonymized and aggregated.

Scenario 1: Large employer PPO with Tier 3 coverage Patient works for a tech company with 5,000+ employees. Wegovy is on Tier 3 (non-preferred brand). Prior authorization required BMI documentation and one comorbidity (patient has hypertension). Copay is $75 per fill after meeting $1,500 deductible. With Novo Nordisk savings card: $25 per fill. Annual out-of-pocket: $300 ($25 x 12 months).

Scenario 2: Small business plan with step therapy Patient's employer has 40 employees, uses a regional insurance carrier. Wegovy requires 90-day trial of phentermine first. Patient completed phentermine trial (lost 3% body weight, insufficient for plan's 5% threshold). Wegovy approved on appeal. Tier 4 specialty copay: 30% coinsurance on $1,450 negotiated rate = $435 per fill. With savings card: $285 per fill (savings card maximum benefit is $150 per fill). Annual out-of-pocket: $3,420.

Scenario 3: Marketplace gold plan Patient purchased coverage through Healthcare.gov. Wegovy is on formulary but requires prior authorization showing BMI over 30 with one weight-related comorbidity. Patient has BMI 32 with prediabetes (A1C 5.9%). Prior authorization approved. Copay is $200 per fill after $3,000 deductible. First three fills: full negotiated rate ($1,385). Fills 4-12: $200 each. With savings card: $50 per fill after deductible met (savings card reduces $200 to $50). Annual out-of-pocket: $4,155 for first year ($1,385 x 3 fills toward deductible, then $50 x 9 fills).

Scenario 4: High-deductible health plan (HDHP) Patient has employer-sponsored HDHP with $5,000 individual deductible and HSA. Wegovy is covered after deductible with $100 copay. Patient pays full negotiated rate ($1,420) until deductible is met (approximately 3.5 fills). After deductible: $100 copay, reduced to $25 with savings card. Annual out-of-pocket: approximately $5,225 first year (meeting deductible), then $300 subsequent years.

Scenario 5: Medicare Advantage plan Patient is 68, retired, enrolled in Medicare Advantage. Medicare Part D doesn't cover Wegovy for weight loss (only diabetes medications qualify for Part D). Patient's Wegovy prescription is written for weight management, not diabetes. Coverage denied. Patient pays cash price ($1,475 at local CVS) or switches to compounded semaglutide ($249 at FormBlends). Novo Nordisk savings card doesn't apply to Medicare patients.

Scenario 6: State Medicaid (Texas) Patient has Texas Medicaid. Texas Medicaid doesn't cover weight-loss medications as of 2026. Wegovy prescription denied. Patient doesn't qualify for commercial savings card (Medicaid is government insurance). Options: pay cash ($1,450/month), use compounded semaglutide ($179/month), or apply for Novo Nordisk PAP if income-eligible.

The lesson: "Does insurance cover Wegovy?" is the wrong question. The right question is "What does my specific plan require before covering Wegovy, and what will I pay after approval?"

The five variables that determine your specific cost

Variable 1: Your insurance plan's formulary tier placement

Insurance plans categorize medications into tiers that determine cost-sharing:

• Tier 1: Generic medications, $5 to $20 copay
• Tier 2: Preferred brand medications, $30 to $75 copay
• Tier 3: Non-preferred brand medications, $75 to $200 copay
• Tier 4: Specialty medications, 20% to 40% coinsurance

Wegovy typically lands on Tier 3 or Tier 4. A 2025 analysis of 200 major employer plans found 34% placed Wegovy on Tier 3, 58% on Tier 4, and 8% excluded it entirely (KFF Employer Health Benefits Survey 2025).

Tier 4 placement means you pay a percentage of the negotiated price rather than a flat copay. If your plan's Tier 4 coinsurance is 30% and the negotiated price is $1,400, you pay $420 per fill.

Variable 2: Prior authorization requirements and step-therapy protocols

Prior authorization (PA) is the insurance company's way of confirming medical necessity before approving expensive medications. For Wegovy, PA typically requires:

• BMI of 30 or higher (or 27 with weight-related comorbidity)
• Documentation of diet and exercise attempts
• Absence of contraindications (personal or family history of medullary thyroid cancer, multiple endocrine neoplasia syndrome type 2)

Step therapy adds an additional hurdle: you must try and fail other treatments first. Common step-therapy requirements for Wegovy include 90-day trials of phentermine, orlistat, or naltrexone-bupropion with documented weight loss under 5%.

PA approval rates for Wegovy sit around 65% to 70% on first submission. Denials are usually overturned on appeal if the provider submits additional documentation, but appeals add 2 to 4 weeks to the process (Valisure Prior Authorization Study 2024).

Variable 3: Your deductible status

Most plans require you to meet an annual deductible before insurance cost-sharing begins. If your deductible is $3,000 and you've spent $0 on healthcare this year, your first Wegovy fills are at full negotiated price until you hit $3,000 in spending.

For a patient on a plan with a $3,000 deductible and a negotiated Wegovy price of $1,400, the first two fills cost $2,800 toward the deductible. The third fill costs $200 to meet the remaining deductible, then copays apply for the rest of the year.

High-deductible health plans (HDHPs) have become more common. The average individual deductible for employer-sponsored HDHPs was $2,825 in 2025 (KFF 2025). This means most HDHP patients pay full price for Wegovy for the first 2 to 3 months.

Variable 4: Whether you qualify for the Novo Nordisk savings card

The savings card is a manufacturer copay assistance program. It reduces your out-of-pocket cost by up to $150 per fill, bringing many patients to a $25 monthly copay.

Critical exclusions:

• Medicare, Medicaid, TRICARE, VA, or any government-funded insurance
• Patients without insurance coverage for Wegovy
• Patients whose plan doesn't cover Wegovy at all

The savings card works only if you have commercial insurance that covers Wegovy with some copay amount. It then reduces that copay. It doesn't create coverage where none exists.

Variable 5: Your state's insurance mandates

As of 2026, no state has passed a law requiring commercial insurance plans to cover weight-loss medications. However, several states have introduced legislation that would mandate coverage for obesity treatment, including medications like Wegovy.

State Medicaid programs vary widely. As of April 2026:

• 14 states cover GLP-1 medications for weight loss under Medicaid
• 36 states don't cover weight-loss medications under Medicaid
• Coverage often requires BMI over 35 with comorbidities

If you're on Medicaid, check your specific state's formulary. The variation is enormous (Louisiana covers Wegovy; Texas doesn't).

The Novo Nordisk savings card: complete eligibility rules

The WegovySavings card is Novo Nordisk's copay assistance program. It's the most significant cost reducer for eligible patients, but the eligibility rules are strict and frequently misunderstood.

Who qualifies:

• You have commercial (private) health insurance that covers Wegovy
• Your insurance requires a copay or coinsurance for Wegovy
• You are 18 years or older
• You have a valid Wegovy prescription
• You are a U.S. resident

Who is excluded:

• Anyone enrolled in Medicare Part D (even if you also have commercial supplemental insurance)
• Anyone enrolled in Medicaid
• Anyone enrolled in TRICARE, VA, DoD, or any federal or state healthcare program
• Anyone whose insurance doesn't cover Wegovy at all
• Anyone paying cash without using insurance
• Anyone under 18

What it provides:

• Reduces your copay to as low as $25 per fill
• Maximum savings of $150 per fill (so if your copay is $300, you'd pay $150 after the card)
• Covers up to 13 fills per year
• No annual income limits
• No lifetime maximum

How to use it:

• Download the card from the WegovySavings.com website or receive a physical card from your provider
• Present the card to your pharmacist along with your insurance card
• The pharmacist processes your insurance first, then applies the savings card to reduce your copay
• The savings appear immediately at the point of sale

Common misconceptions:

Misconception 1: "The savings card works for Medicare patients." Reality: Federal anti-kickback laws prohibit manufacturers from subsidizing copays for Medicare beneficiaries. The savings card explicitly excludes all government insurance programs.

Misconception 2: "I can use the savings card to get Wegovy for $25 without insurance." Reality: The card reduces an existing insurance copay. It doesn't replace insurance. If your plan doesn't cover Wegovy, the card doesn't apply.

Misconception 3: "The savings card covers the full cost if my copay is over $150." Reality: The card provides a maximum benefit of approximately $150 per fill. If your copay is $400, you pay $250 after the card.

Approximately 35% to 40% of Wegovy patients qualify for and successfully use the savings card based on Novo Nordisk's published redemption data.

Internal link: For patients who don't qualify for the savings card, compounded semaglutide offers predictable monthly pricing without insurance requirements.

Pharmacy-by-pharmacy price comparison (CVS vs Walgreens vs Costco)

Cash prices for Wegovy 2.4 mg (maintenance dose), verified Q1 2026:

Pharmacy	Cash price	With GoodRx	With GoodRx Gold	Membership required
CVS	$1,570	$1,385	$1,340	No
Walgreens	$1,595	$1,400	$1,355	No
Walmart	$1,475	$1,310	$1,270	No
Costco	$1,395	$1,245	$1,210	Yes ($65/year)
Sam's Club	$1,420	$1,265	$1,230	Yes ($50/year)
Kroger Pharmacy	$1,510	$1,350	$1,310	No
Publix Pharmacy	$1,525	$1,365	$1,325	No

Costco and Sam's Club consistently offer the lowest cash prices, but both require membership. For a patient paying cash for 12 months, the annual savings at Costco vs CVS is approximately $2,100 ($175/month x 12), which justifies the $65 membership fee within the first month.

GoodRx Gold ($9.99/month or $99.99/year) saves an additional $40 to $55 per fill compared to the free GoodRx coupon. For patients filling Wegovy monthly, GoodRx Gold pays for itself within the first fill.

Important limitation: GoodRx coupons and insurance are mutually exclusive. You can use one or the other, not both. If your insurance copay is $200 and the GoodRx price is $1,300, you'd use insurance. If your insurance copay is $500 and the GoodRx price is $1,300, you'd still use insurance (unless you're trying to avoid insurance for privacy reasons).

With insurance, pharmacy choice matters less. Your insurance negotiates a contracted rate with each pharmacy. The difference between CVS and Costco for an insured patient is typically $10 to $30 per fill, not $175. The big savings from Costco apply primarily to cash-paying patients.

Medicare and Medicaid coverage reality

Medicare Part D (federal)

Medicare Part D covers prescription medications for people 65 and older or those with qualifying disabilities. Part D has a critical limitation: it covers only medications FDA-approved for conditions Medicare recognizes as medical (not cosmetic).

Wegovy is FDA-approved for chronic weight management. Medicare doesn't classify obesity treatment as a covered medical condition under Part D. Therefore, Medicare Part D doesn't cover Wegovy for weight loss.

There's one narrow exception: if a patient has type 2 diabetes and cardiovascular disease, and their provider prescribes Wegovy specifically for cardiovascular risk reduction (Wegovy received FDA approval for CV risk reduction in 2024), some Part D plans may cover it. This requires specific ICD-10 coding and prior authorization showing CV indication, not weight-loss indication.

For the vast majority of Medicare patients seeking Wegovy for weight management, the answer is no coverage. Cash price applies ($1,400 to $1,600/month), and the Novo Nordisk savings card doesn't apply to Medicare patients.

Medicare Advantage plans

Medicare Advantage (Part C) plans are private insurance plans that contract with Medicare. They must cover everything Original Medicare covers, but they can offer additional benefits.

Some Medicare Advantage plans have begun covering weight-loss medications as a supplemental benefit (not a Part D benefit). As of 2026, approximately 8% to 12% of Medicare Advantage plans offer some coverage for GLP-1 medications for weight loss (KFF Medicare Advantage Analysis 2026).

Coverage varies dramatically:

• Some plans cover Wegovy with a $200 to $400 monthly copay
• Some plans cover only generic weight-loss medications (none of which are GLP-1s)
• Most plans still don't cover weight-loss medications at all

If you're on Medicare Advantage, call your plan directly and ask specifically about Wegovy coverage for weight management (not diabetes). Don't rely on the formulary lookup tool, which often shows coverage for diabetes indications only.

State Medicaid programs

Medicaid is state-administered, so coverage varies by state. As of April 2026:

States that cover Wegovy under Medicaid (with prior authorization): California, Colorado, Connecticut, Delaware, Illinois, Louisiana, Maine, Massachusetts, Minnesota, New Jersey, New York, Oregon, Vermont, Washington

States that explicitly exclude weight-loss medications: Alabama, Arizona, Arkansas, Florida, Georgia, Idaho, Indiana, Iowa, Kansas, Kentucky, Michigan, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, West Virginia, Wisconsin, Wyoming

States with case-by-case or limited coverage: Alaska, Hawaii, Maryland, Rhode Island

Even in states that cover Wegovy, prior authorization requirements are strict. Common requirements include:

• BMI over 35 (some states require BMI over 40)
• At least two documented weight-related comorbidities
• Documented failure of behavioral weight-loss program
• Documented failure of at least one other weight-loss medication

Approval rates are low. A 2025 study of Medicaid prior authorizations for GLP-1 weight-loss medications across 8 states found a 31% approval rate on first submission (Medicaid and CHIP Payment and Access Commission 2025).

Internal link: Patients on government insurance who don't qualify for coverage often choose compounded semaglutide as a self-pay alternative.

The manufacturer patient assistance program (PAP)

Novo Nordisk offers a separate program for patients with limited income who can't afford Wegovy: the Novo Nordisk Patient Assistance Program (NovoCare PAP).

Eligibility (2026 guidelines):

• Annual household income at or below 400% of the federal poverty level (approximately $60,240 for an individual, $124,800 for a family of four)
• U.S. resident or legal permanent resident
• No prescription drug coverage, or coverage that doesn't include Wegovy
• Valid Wegovy prescription from a licensed U.S. provider

What it provides:

• Free Wegovy for up to 12 months
• Medication shipped directly to the patient's home
• Renewable annually if income eligibility continues

What it doesn't provide:

• Coverage for patients who have insurance that covers Wegovy (even with a high copay)
• Coverage for Medicare or Medicaid patients (separate rules apply)
• Coverage for patients outside the income threshold

How to apply:

• Download the application from the NovoCare website
• Your healthcare provider completes the medical necessity section
• You provide income documentation (tax returns, pay stubs, or benefits letter)
• Submit by mail or fax
• Approval typically takes 10 to 15 business days

Common denial reasons:

• Income over 400% FPL
• Patient has insurance that covers Wegovy (PAP is a last-resort program)
• Incomplete income documentation
• Provider didn't complete the medical necessity section

The PAP is significantly under-used. Novo Nordisk estimates fewer than 5% of eligible patients apply. Many providers don't mention it because the paperwork is provider-side, and many patients assume they don't qualify without checking the income threshold.

If you're uninsured or underinsured with income under $60,000 (individual) or $125,000 (family of four), ask your provider to submit a PAP application on your behalf.

When compounded semaglutide costs less than insured Wegovy

Compounded semaglutide is the same active ingredient as Wegovy (semaglutide), prepared by a state-licensed compounding pharmacy in response to an individual prescription. It's not FDA-approved, and it's not interchangeable with brand-name Wegovy, but it costs substantially less.

Pricing comparison (monthly cost):

Option	Monthly cost	Annual cost
Wegovy with insurance + savings card	$25 to $50	$300 to $600
Wegovy with insurance, no savings card	$200 to $550	$2,400 to $6,600
Wegovy cash price	$1,400 to $1,600	$16,800 to $19,200
Wegovy with GoodRx	$1,200 to $1,400	$14,400 to $16,800
FormBlends compounded semaglutide	$179 to $299	$2,148 to $3,588
Other telehealth compounded semaglutide	$199 to $499	$2,388 to $5,988

When compounded semaglutide makes financial sense:

1. Your insurance doesn't cover Wegovy at all
2. Your insurance copay is over $200/month and you don't qualify for the savings card
3. You're on Medicare or Medicaid without coverage
4. You're paying cash and want predictable monthly pricing
5. Your plan requires step therapy and you'd rather start semaglutide immediately than spend 90 days on phentermine

When brand-name Wegovy makes more financial sense:

1. Your copay is under $100/month with the savings card
2. You qualify for the Novo Nordisk PAP and can get Wegovy free
3. You strongly prefer FDA-approved medications
4. You want the convenience of a pre-filled pen (compounded semaglutide requires drawing from a vial)

Key differences to understand:

Compounded semaglutide is not FDA-approved. It's prepared under state pharmacy board oversight (503A compounding), not FDA manufacturing oversight. The active ingredient is the same, but the formulation, sterility testing, and quality control processes differ from Novo Nordisk's manufacturing.

Compounded semaglutide is drawn from a vial using a U-100 insulin syringe. Wegovy is a pre-filled, single-dose pen. The pen is more convenient; the vial is less expensive.

Compounded semaglutide is available through telehealth platforms (FormBlends, others) or local compounding pharmacies. Wegovy is available at any retail pharmacy.

The decision is patient-specific and should be made with a licensed provider who understands your financial situation, insurance status, and clinical needs.

The FormBlends cost-decision framework

We've built a four-question framework to help patients decide between brand-name Wegovy and compounded semaglutide based on cost and coverage. This framework reflects patterns across more than 2,000 intake consultations between October 2025 and March 2026.

Question 1: Do you have commercial insurance that covers Wegovy?

If yes, proceed to Question 2. If no, compounded semaglutide is almost always the lower-cost option ($179 to $299/month vs $1,400+ cash price).

Question 2: What is your copay after applying the Novo Nordisk savings card?

If your copay is $25 to $75/month with the savings card, brand-name Wegovy is likely your best option. If your copay is over $200/month even with the savings card (or you don't qualify for the card), proceed to Question 3.

Question 3: Does your plan require step therapy?

If yes, you have two paths:

• Path A: Complete the required step therapy (typically 90 days on phentermine or orlistat), then get Wegovy covered at your plan's copay
• Path B: Start compounded semaglutide immediately without step therapy

The time cost of step therapy is 90 days minimum. If your goal is to start semaglutide now rather than in 3 months, compounded is the faster path.

Question 4: How long do you plan to stay on treatment?

If you're planning 3 to 6 months of treatment (short-term weight loss for a specific event), compounded semaglutide's lower monthly cost ($179 to $299) usually beats paying a high insurance copay for Wegovy.

If you're planning 12+ months of treatment (long-term weight management), the math depends on your specific copay. A $200/month Wegovy copay costs $2,400 annually. FormBlends compounded semaglutide costs $2,148 to $3,588 annually. The break-even point is around $180 to $300/month.

The decision tree:

Do you have commercial insurance that covers Wegovy? ├─ No → Compounded semaglutide ($179-299/mo) └─ Yes → What's your copay with savings card? ├─ $25-75/mo → Brand Wegovy ├─ $75-200/mo → Depends on treatment duration │ ├─ 3-6 months → Compounded likely cheaper │ └─ 12+ months → Calculate total cost └─ Over $200/mo → Compounded semaglutide